Verdiperstat
Based on 7 publication(s) in Google Scholar
Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.69%
- CAS 番号: 890655-80-8
- 分子式: C11H15N3O2S
- 分子量:253.32
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-111341
AZD5904Glutathione Peroxidase Inhibitor -
HY-145581
MitiperstatMPO Inhibitor -
HY-100873
PF-1355MPO Inhibitor -
HY-115486
MPO-IN-28MPO Inhibitor -
HY-10431
SB-431542TGF-β Receptor Kinase Inhibitor -
HY-18739
Phorbol 12-myristate 13-acetatePKC Activator -
HY-19321
PF-06282999Myeloperoxidase Inhibitor -
HY-13418A
DorsomorphinAMPK Inhibitor -
HY-14539
ClozapineAntipsychotic Agent -
HY-17031
SBE-β-CDExcipient -
HY-B0880
4-AminobenzohydrazideGlutathione Peroxidase Inhibitor -
HY-139915
MPO-IN-1Myeloperoxidase Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Verdiperstat
More- Sci Adv. 2025 Jul 11;11(28):eadu5915. [Abstract]
- J Immunother Cancer. 2023 Feb;11(2):e005837. [Abstract]
- Antioxidants (Basel). 2025 Dec 8;14(12):1473. [Abstract]
- J Med Chem. 2026 Jun 11;69(11):13670-13682. [Abstract]
- J Inflamm (Lond). 2025 Aug 12;22(1):33. [Abstract]
- Cancer Immunol Immunother. 2024 Feb 17;73(3):57. [Abstract]
- bioRxiv. 2020 Nov 24:2020.11.24.393405. [Abstract]
生物活性
製品説明
IC50 & Target
IC50: 630 nM (Myeloperoxidase)[1]
体外実験
Verdiperstat (AZD3241) is a myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and is used in the research of neurodegenerative brain disorders[1]. Verdiperstat (AZD3241) selectively and irreversibly inhibits myeloperoxidase, and may involves reduction of oxidative stress leading to reduction of sustained neuroinflammation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 890655-80-8
-
性状 Solid
-
分子量 253.32
-
分子式 C11H15N3O2S
-
Color White to light brown
-
SMILES
O=C(N1)C(NC=C2)=C2N(CCOC(C)C)C1=S
-
別名
AZD3241
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils. [Abstract]2025 Jul 11;11(28):eadu5915. PMID: 40644540 -
J Immunother Cancer
2023 Feb;11(2):e005837. PMID: 36805920 -
Antioxidants (Basel)
Imaging Reactive Oxygen Species with L-012 Reveals Neutrophil Extracellular Trap Formation in Pancreatic Ductal Adenocarcinoma. [Abstract]2025 Dec 8;14(12):1473. PMID: 41462673 -
J Med Chem
Kinetically Inert MRI/PET Probes with Myeloperoxidase-Triggered Covalent Capture for Quantitative Imaging of Acute Pancreatitis. [Abstract]2026 Jun 11;69(11):13670-13682. PMID: 42154911 -
J Inflamm (Lond)
Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition. [Abstract]2025 Aug 12;22(1):33. PMID: 40797324 -
Cancer Immunol Immunother
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer. [Abstract]2024 Feb 17;73(3):57. PMID: 38367056 -
bioRxiv
Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking. [Abstract]2020 Nov 24:2020.11.24.393405. PMID: 33269349
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (394.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.87 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Johnström P, et al. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol. 2015 Jun;42(6):555-60. [Content Brief]
[2]. Jucaite A, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9476 mL | 19.7379 mL | 39.4758 mL | 98.6894 mL |
| 5 mM | 0.7895 mL | 3.9476 mL | 7.8952 mL | 19.7379 mL | |
| 10 mM | 0.3948 mL | 1.9738 mL | 3.9476 mL | 9.8689 mL | |
| 15 mM | 0.2632 mL | 1.3159 mL | 2.6317 mL | 6.5793 mL | |
| 20 mM | 0.1974 mL | 0.9869 mL | 1.9738 mL | 4.9345 mL | |
| 25 mM | 0.1579 mL | 0.7895 mL | 1.5790 mL | 3.9476 mL | |
| 30 mM | 0.1316 mL | 0.6579 mL | 1.3159 mL | 3.2896 mL | |
| 40 mM | 0.0987 mL | 0.4934 mL | 0.9869 mL | 2.4672 mL | |
| 50 mM | 0.0790 mL | 0.3948 mL | 0.7895 mL | 1.9738 mL | |
| 60 mM | 0.0658 mL | 0.3290 mL | 0.6579 mL | 1.6448 mL | |
| 80 mM | 0.0493 mL | 0.2467 mL | 0.4934 mL | 1.2336 mL | |
| 100 mM | 0.0395 mL | 0.1974 mL | 0.3948 mL | 0.9869 mL |
Verdiperstat 関連分類
HY-17646 関連分類
Powered by Bioz